医学
维多利祖马布
中止
不利影响
克罗恩病
溃疡性结肠炎
斯科普斯
疾病
内科学
炎症性肠病
梅德林
政治学
法学
作者
Mathurin Fuméry,A. Buisson
标识
DOI:10.1016/s2468-1253(23)00356-4
摘要
TNF antagonists, anti-integrin antibodies, and antibodies against IL-12 and IL-23 are the main therapeutic options in Crohn's disease. 1 Torres J Mehandru S Colombel JF Peyrin-Biroulet L Crohn's disease. Lancet. 2017; 389: 1741-1755 Summary Full Text Full Text PDF PubMed Scopus (1331) Google Scholar Upadacitinib, an oral, small-molecule JAK antagonist was also recently approved to treat the disease. 2 Loftus Jr, EV Panés J Lacerda AP et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023; 388: 1966-1980 Crossref Scopus (20) Google Scholar Although these agents represent major advances in the treatment of Crohn's disease, many patients do not respond, lose response over time, or have adverse events leading to drug discontinuation. 3 Singh S Murad MH Fumery M et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021; 6: 1002-1014 Summary Full Text Full Text PDF PubMed Scopus (80) Google Scholar , 4 Peyrin-Biroulet L Danese S Argollo M et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019; 17: 838-846 Summary Full Text Full Text PDF PubMed Scopus (104) Google Scholar Thus, there is a growing demand for novel therapeutic agents targeting alternative disease mechanisms. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialPatients receiving guselkumab intravenous induction and subcutaneous maintenance treatment achieved high rates of clinical and endoscopic efficacy up to week 48. No new safety concerns were identified. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI